Bright Minds to attend PWS research symposium in Philadelphia

• Company will attend the FPWR 2026 Research Symposium on Oct. 7-8.
• It will also participate in the PWS Family Conference on Oct. 9-10.
• Bright Minds said its NOVA study of BMB-101 is under way.
• The company also said it rescinded an officer’s prior option exercise for 44,500 shares.

Bright Minds Biosciences said on Sept. 30 it will take part in the Foundation for Prader-Willi Research 2026 Research Symposium on Oct. 7-8 and the PWS Family Conference on Oct. 9-10. Both meetings are set for the Marriott Philadelphia Downtown.

Bright Minds to attend PWS research symposium in Philadelphia

The company said the FPWR meeting brings together families, caregivers, clinicians, researchers and industry. Bright Minds said its participation reflects its commitment to developing a therapy that addresses hyperphagia and neurobehavioral symptoms in Prader-Willi syndrome.

Chief Executive Officer Ian McDonald said: "There is no therapy today that adequately addresses the full burden of Prader-Willi Syndrome: the relentless hunger and the behavioral and psychiatric challenges that families live with every day."

McDonald also said the FPWR community has shaped how the company thinks about the disease, from outcome measures to study design. He said the company is proud to support this year's meeting and spend time with families and researchers.

Clinical program

Bright Minds said its NOVA study of BMB-101 is under way. The randomized, double-blind, placebo-controlled Phase 2a study is assessing hyperphagia, PWS-associated behaviors, safety and tolerability over a 16-week treatment period, with an optional open-label extension.

The company said individuals with PWS have reduced levels of functional 5-HT2C receptors. It said BMB-101 is being developed as a highly selective, Gq-biased 5-HT2C agonist.

Bright Minds said the program is designed to restore signaling through that pathway while avoiding receptor desensitization and 5-HT2B-related cardiac liabilities that limited earlier serotonergic agents.

Corporate update

Bright Minds also said it has entered into a mutual rescission and release agreement with an officer. The agreement rescinds the officer's prior exercise of stock options in respect of 44,500 common shares.

The 44,500 shares issued on that exercise will be returned to treasury and cancelled. The company said the aggregate exercise price will be refunded and the options restored on their original terms, including exercise price, vesting schedule and expiry date.

In November 2025, Bright Minds expanded its Scientific Advisory Board with four global PWS experts, including Theresa V. Strong, Jennifer L. Miller, Elizabeth Roof and Tania Markovic.